Key result
Off-label cardiac resynchronization therapy enabled successful withdrawal from intravenous inotropes in 64% of end-stage heart failure patients, which was associated with longer event-free survival.
Why the study?
Does off-label cardiac resynchronization therapy (CRT) improve successful withdrawal from inotropic support and survival in end-stage heart failure patients dependent on continuous intravenous inotropes?
Population
14 end-stage heart failure patients dependent on continuous intravenous inotropes at the time of CRT…
Design
Cohort
Authors
Loading...
May support off-label CRT for inotrope withdrawal in end-stage HF; hypothesis-generating and requires randomized confirmation before practice change.
Cohort (n=14)
Does off-label cardiac resynchronization therapy (CRT) improve successful withdrawal from inotropic support and survival in end-stage heart failure patients dependent on continuous intravenous inotropes?
Off-label CRT may facilitate withdrawal from continuous intravenous inotropes and improve survival in select end-stage heart failure patients, particularly those with lower grades of mitral regurgitation.
Hara et al. (2011) conducted a cohort in End-stage heart failure dependent on continuous intravenous inotrope (n=14). Cardiac resynchronization therapy (CRT) was evaluated on Successful withdrawal from inotropic support. Off-label cardiac resynchronization therapy enabled successful withdrawal from intravenous inotropes in 64% of end-stage heart failure patients, which was associated with longer event-free survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: